Tests ARGX-121 in adults with IgA nephropathy kidney disease
Tests ARGX-121 against placebo in adults with IgA nephropathy, a kidney disease.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
Key facts
- Where
- Barcelona, Lleida, Manises, and Murcia, SpainSee the 4 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with IgA nephropathy (IgAN) confirmed by a kidney biopsy. It tests ARGX-121 against placebo.
- Age
- At least 18 years old.
- Sex
- Men and women can join. Women must not be pregnant.
- Disease stage
- IgAN diagnosed by a doctor and confirmed by a biopsy. The record names no stage.
Main reasons for not taking part
- Another autoimmune disease or condition that makes it hard to judge IgAN symptoms
- IgAN caused by another disease (secondary IgAN)
- History of cancer
- Active infection of concern
- Recent major surgery or organ transplant
Read by machine on 12 November 2026.
Where in Spain
- Hospital Clinic de BarcelonaBarcelona, SpainTaking people
- Hospital Universitari Arnau De Vilanova De La Gerencia Territorial De LleidaLleida, SpainTaking people
- Hospital de ManisesManises, SpainTaking people
- University Clinical Hospital Virgen De La ArrixacaMurcia, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- argenx
- Trial code
- NCT07773727EU 2026-525638-43-00
- Record updated
- 27 October 2026
- Original description
The study will assess how ARGX-121 affects immunoglobulin A nephropathy (IgAN) disease outcomes, such as renal function, how it is distributed and eliminated from the body, and how the immune system responds in adults with IgAN.Read full original descriptionShow less
A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ARGX-121 SC in Adult Participants With Primary IgA Nephropathy
The study will assess how ARGX-121 affects immunoglobulin A nephropathy (IgAN) disease outcomes, such as renal function, how it is distributed and eliminated from the body, and how the immune system responds in adults with IgAN.
While in the study, participants will continue to receive their usual medical care and medications for IgA nephropathy, unless the study doctor confirms otherwise.
The study will include a double blinded period, followed by an active drug period, and conclude with a follow up period. The total study duration for participants will be approximately 72 weeks, with a maximum of 52 weeks on ARGX-121.
Inclusion: Males and females (not pregnant); At least 18 years old; Clinically diagnosed with IgAN with biopsy confirmation.
Exclusion: Recent Major surgery or organ transplant; Diagnosis of another autoimmune disease or known medical condition that would interfere with accurate assessment of clinical systems of IgAN; History of Malignancy; Active infection of concern; Has secondary form of IgAN leading to IgA deposits.